Evidence map›Paper›PMID 35668159›Full record

SynthesisMolecular psychiatry2023

A systematic review and meta-analysis of long term physical and mental sequelae of COVID-19 pandemic: call for research priority and action.

Na Zeng, Yi-Miao Zhao, Wei Yan, Chao Li, Qing-Dong Lu, Lin Liu, Shu-Yu Ni, Huan Mei, Kai Yuan, Le Shi and 13 more

Registry-linked trialOpen access · bronzeAbstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Molecular psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06178952 (Transcranial Pulse Stimulation), which is not on this map. Cited by 192 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
192citing papers in PubMed, 12 pooled it
40.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06178952 narecruitingnot on this mapstarted 2024, after this paper: background citation

Transcranial Pulse Stimulation (TPS) in Post-COVID-19

TypeinterventionalSponsorMedical University of ViennaRan2024 to 2027Enrolled102ConditionsPost-COVID-19 Syndrome, FatigueArmsTranscranial pulse stimulation Verum, Transcranial pulse stimulation Sham
3 · Its place in the literature

Who cites it

192 citing papers in PubMed, 12 syntheses or guidelines pooled it, 330 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Global prevalence of post-COVID-19 condition: a systematic review and meta-analysis of prospective evidence.Health promotion and chronic disease prevention in Canada : research, policy and practice · 2025
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Trial
  15. A digital intervention for cognitive deficits following COVID-19: a randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

132 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 3 countries.

Na Zeng *National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China.
Yi-Miao Zhao *National Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China.
Wei Yan *Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, Beijing, 100191, China.ORCID http://orcid.org/0000-0002-5866-6230
Chao LiBeijing Friendship Hospital, Capital Medical University, Beijing, China.
Qing-Dong LuNational Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China.
Lin LiuNational Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China.ORCID http://orcid.org/0000-0003-2685-5827
Shu-Yu NiNational Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China.
Huan MeiNational Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China.
Kai YuanPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, Beijing, 100191, China.ORCID http://orcid.org/0000-0002-3498-8163
Le ShiPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, Beijing, 100191, China.ORCID http://orcid.org/0000-0003-4750-3492
Peng LiPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, Beijing, 100191, China.
Teng-Teng FanPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, Beijing, 100191, China.
Jun-Liang YuanPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, Beijing, 100191, China.
Michael V VitielloDepartment of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-9776-0473
Thomas KostenDepartment of Psychiatry, Pharmacology, Neuroscience, Immunology, Baylor College of Medicine, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0003-1505-555X
Alexandra L KondratiukNIHR Health Protection Research Unit in Respiratory Infections, National Heart and Lung Institute, Imperial College, London, W2 1NY, UK.ORCID http://orcid.org/0000-0002-9134-5009
Hong-Qiang SunPeking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Chinese Academy of Medical Sciences Research Unit (No. 2018RU006), Peking University, Beijing, 100191, China.
Xiang-Dong TangSleep Medicine Center, Department of Respiratory and Critical Care Medicine, Mental Health Center and Translational Neuroscience Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.ORCID http://orcid.org/0000-0001-6876-3328
Mei-Yan LiuBeijing Anzhen Hospital, Capital Medical University, Beijing, China.
Ajit LalvaniNIHR Health Protection Research Unit in Respiratory Infections, National Heart and Lung Institute, Imperial College, London, W2 1NY, UK.
Jie ShiNational Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China. shijie@bjmu.edu.cn.ORCID http://orcid.org/0000-0001-6567-8160
Yan-Ping BaoNational Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China. baoyp@bjmu.edu.cn.ORCID http://orcid.org/0000-0002-1881-0939
Lin LuNational Institute on Drug Dependence and Beijing Key Laboratory of Drug Dependence, Peking University, Beijing, China. linlu@bjmu.edu.cn.ORCID http://orcid.org/0000-0003-0742-9072
Chinese Academy of Medical Sciences & Peking Union Medical College · CNPeking University · CNCapital Medical University · CNNIHR Imperial Biomedical Research Centre · GBBaylor College of Medicine · USSichuan University · CNUniversity of Washington · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The long-term physical and mental sequelae of COVID-19 are a growing public health concern, yet there is considerable uncertainty about their prevalence, persistence and predictors. We conducted a comprehensive, up-to-date meta-analysis of survivors' health consequences and sequelae for COVID-19. PubMed, Embase and the Cochrane Library were searched through Sep 30th, 2021. Observational studies that reported the prevalence of sequelae of COVID-19 were included. Two reviewers independently undertook the data extraction and quality assessment. Of the 36,625 records identified, a total of 151 studies were included involving 1,285,407 participants from thirty-two countries. At least one sequelae symptom occurred in 50.1% (95% CI 45.4-54.8) of COVID-19 survivors for up to 12 months after infection. The most common investigation findings included abnormalities on lung CT (56.9%, 95% CI 46.2-67.3) and abnormal pulmonary function tests (45.6%, 95% CI 36.3-55.0), followed by generalized symptoms, such as fatigue (28.7%, 95% CI 21.0-37.0), psychiatric symptoms (19.7%, 95% CI 16.1-23.6) mainly depression (18.3%, 95% CI 13.3-23.8) and PTSD (17.9%, 95% CI 11.6-25.3), and neurological symptoms (18.7%, 95% CI 16.2-21.4), such as cognitive deficits (19.7%, 95% CI 8.8-33.4) and memory impairment (17.5%, 95% CI 8.1-29.6). Subgroup analysis showed that participants with a higher risk of long-term sequelae were older, mostly male, living in a high-income country, with more severe status at acute infection. Individuals with severe infection suffered more from PTSD, sleep disturbance, cognitive deficits, concentration impairment, and gustatory dysfunction. Survivors with mild infection had high burden of anxiety and memory impairment after recovery. Our findings suggest that after recovery from acute COVID-19, half of survivors still have a high burden of either physical or mental sequelae up to at least 12 months. It is important to provide urgent and appropriate prevention and intervention management to preclude persistent or emerging long-term sequelae and to promote the physical and psychiatric wellbeing of COVID-19 survivors.

Indexed as

COVID-19AnxietyFemaleHumansLungMalePandemicsPost-Acute COVID-19 SyndromeRisk Factors

Identifiers

PMID35668159
PMCPMC9168643
OpenAlexW4281750388

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.